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Reverse genetics of negative-sense RNA viruses, which enables one to generate virus entirely from cloned cDNA, has
progressed rapidly over the past decade. However, despite the relative ease with which nonsegmented negative-sense RNA
viruses can now be produced from plasmids, the ability to generate viruses with segmented genomes has lagged
considerably, largely because of the inherent technical difficulties in providing all viral RNAs and proteins from cloned cDNA.
A breakthrough in reverse genetics technology in the influenza virus field came in 1999, when we (Neumann et al., 1999, Proc.
Natl. Acad. Sci. USA 96, 9345–9350) and others (Fodor et al., 1999, J. Virol. 73, 9679–9682) exploited a new approach to viral
RNA production. In this review, we discuss the background for this advance, the systems that are now available for the
generation of influenza viruses, and the implications of these developments for the future of virus research. © 2001 Academic
PressInfluenza virus belongs to the family Orthomyxoviridae
nd contains a segmented RNA genome of negative
olarity. In contrast to most other negative-sense RNA
iruses, influenza virus replicates in the nucleus of in-
ected cells (reviewed in Lamb and Krug, 1996). After
eceptor-mediated endocytosis and fusion of the viral
nd cellular membranes, the viral ribonucleoprotein
vRNP) complex is released into the cytoplasm. The
RNP complex, composed of the viral RNA (vRNA), nu-
leoprotein (NP), and three polymerase proteins (PB2,
B1, and PA), is transported to the nucleus where tran-
cription and replication occur. The negative-sense
RNA (complementary to mRNA in its orientation) does
ot serve as a direct template for protein synthesis;
ather, the vRNA encapsidated by NP must be tran-
cribed into mRNA by the viral polymerase complex.
uring replication, the vRNA serves as a template for the
ynthesis of a full-length complementary RNA (cRNA),
hich in turn serves as a template for progeny vRNA
ynthesis. Thus, for influenza virus replication, the mini-
al functional unit is the vRNP complex. The generation
f influenza A virus therefore requires eight functional
NP complexes that must be delivered into the cell
ucleus.
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Pathobiological Sciences, School of Veteri-
ary Medicine, University of Wisconsin–Madison, 2015 Linden Drive
est, Madison, WI 53706. Fax: (608) 265-5622. E-mail:
awaokay@svm.vetmed.wisc.edu.
243Attempts to generate influenza virus in the laboratory
began in the 1980s, when replication-competent vRNPs
were isolated from detergent-disrupted viruses (Plotch et
al., 1981) or infected cells (Beaton and Krug, 1986). These
early studies demonstrated that vRNP complexes are
sufficient for the replication of influenza virus RNA, but
synthetic viral RNAs must be assembled into functional
vRNP complexes to artificially generate influenza virus.
This goal was partially reached in the late 1980s, when
Parvin et al. (1989) and later Honda et al. (1990) reported
the reconstitution of functional RNP complexes in vitro.
Purified polymerase and NP proteins formed functional
complexes that transcribed a synthetic RNA template
and, more importantly, full-length viral RNA purified from
virions. With the new-found ability to generate functional
vRNP complexes, researchers directed their attention to
techniques for introducing these (modified) vRNPs into
virions.
In 1989, Palese and colleagues established the first
system for modifying negative-sense RNA viruses (see
Luytjes et al., 1989), ushering in a new era of recombi-
nant virus research using viruses containing vRNA de-
rived solely from cloned cDNA (Fig. 1). Enami et al. (1990)
assembled in vitro transcribed vRNA and purified NP and
polymerase proteins into RNP complexes. Once these
complexes were transfected into eukaryotic cells, helper
virus infection provided the remaining vRNPs, resulting
in a recombinant virus comprised of one of the vRNAs
derived from cloned cDNA. However, in this system, the
vast majority of progeny viruses are helper viruses, re-
quiring strong selection systems based on antibody-
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245MINIREVIEWmediated growth restriction (Barclay and Palese, 1995;
Enami and Palese, 1991; Horimoto and Kawaoka, 1994;
Rowley et al., 1999), temperature sensitivity (Enami et al.,
1991; Li et al., 1995; Yasuda et al., 1994), host-range
restriction (Enami et al., 1990; Subbarao et al., 1993), or
drug resistance (Castrucci and Kawaoka, 1995). Although
selection systems were eventually established for six of
the eight influenza A viral segments [PB2 (Subbarao et
al., 1993), HA (Enami and Palese, 1991), NP (Li et al.,
1995), NA (Enami et al., 1990), M (Castrucci and
Kawaoka, 1995), and NS (Enami et al., 1991)], and for the
HA and NA segments of influenza B virus (Barclay and
Palese, 1995; Rowley et al., 1999), their application was
echnically demanding and the power of selection quite
imited. Consequently, efforts for modifying the influenza
irus genome using this experimental tactic were con-
inued in only a few laboratories.
New impetus was lent to the reverse genetics of in-
luenza virus when Hobom and colleagues, using RNA
olymerase I for the intracellular synthesis of influenza
irus RNA (Fig. 1), established an alternative system for
he generation of influenza viral RNA (see Neumann et
l., 1994). RNA polymerase I is an abundant nuclear
nzyme that transcribes ribosomal RNA (rRNA), which—
ike influenza vRNA—does not contain 59-cap or 39-
oly(A) structures. Moreover, RNA polymerase I initiates
nd terminates transcription at defined promoter and
erminator sequences that do not extend into the tran-
cribed region. Hence, RNA polymerase I transcription
ields transcripts that do not contain additional nucleo-
ides at their 59 or 39 ends. Neumann et al. (1994) cloned
virus-like cDNA under the control of RNA polymerase I
romoter and terminator sequences. After transfection,
his group found that cellular RNA polymerase I synthe-
ized an influenza virus-like RNA. Pleschka et al. (1996)
employed this system to generate recombinant influenza
virus by producing NA vRNP in the nucleus and infecting
cells with helper virus to provide the remaining vRNP
complexes, although selection systems were still re-
quired to isolate recombinant virus from the background
of helper virus. The RNA polymerase I system is more
convenient than the RNP transfection method because it
circumvents the need for in vitro transcription, protein
FIG. 1. Helper virus-dependent systems for the production of infl
ribonucleoprotein (RNP) transfection method, purified polymerase and
unctional RNP complexes. Cells are then transfected with the RNP com
NPs). In the RNA polymerase I system, cells are transfected with a pla
olymerase I promoter (P) and terminator (T) sequences. Transcript
ranscribed, and packaged into progeny virus particles after infection w
o select recombinant virus from the background of helper virus.
FIG. 2. “De novo” synthesis of influenza virus entirely from cloned
olymerase I promoter, a cDNA encoding one of the viral RNAs, and th
he expression of viral proteins required for vRNA replication and tran
per milliliter of supernatant from transfected cells. Cotransfection of cel
production of virus particles lacking genes or possessing genes containing let
virus-like particles for vaccine and gene delivery and functional analysis of vpurification, and in vitro RNP assembly. However, with
oth of these helper virus-dependent systems, the effi-
iencies of virus generation were very low, precluding
he generation of viruses with severe growth defects.
In 1994, Conzelmann and colleagues (see Schnell et
l., 1994) generated rabies virus (family Rhabdoviridae)
rom cloned cDNA for the first time for negative-stranded
NA viruses. A full-length cDNA construct encoding the
ntigenomic positive-sense cRNA was cloned under the
ontrol of the T7 RNA polymerase promoter and the
epatitis delta ribozyme. The resultant plasmid was
ransfected into eukaryotic cells that had been infected
ith recombinant vaccinia virus expressing T7 RNA poly-
erase. Cells were cotransfected with protein expres-
ion plasmids for the components of the viral transcrip-
ion complex, all under control of the T7 RNA polymerase
romoter. Similar approaches led to the production of all
enera of the Rhabdoviridae and Paramyxoviridae fami-
ies (Baron and Barret, 1997; Buchholz et al., 1999; Clarke
t al., 2000; Collins et al., 1995; Durbin et al., 1997; Garcin
t al., 1995; Gassen et al., 2000; He et al., 1997; Hoffman
nd Banerjee, 1997; Jin et al., 1998; Kato et al., 1996;
awson et al., 1995; Peeters et al., 1999; Radecke et al.,
995; Romer-Oberdorfer et al., 1999; Whelan et al., 1995).
These successes were soon translated into advances
with segmented negative-sense RNA viruses.
In 1996, Bridgen and Elliott, using the approach out-
lined by Conzelmann’s group (see Schnell et al., 1994),
produced a recombinant Bunyamwera virus, family Bun-
yaviridae, whose genome is composed of three seg-
ments of negative-sense RNA. Systems were thus in
place for generating both nonsegmented and segmented
negative-sense RNA viruses. A conspicuous exception
was influenza virus, whose generation involves the
added complexity of synthesis of eight (rather than three)
viral RNAs, in addition to the polymerase and nucleopro-
tein from cloned cDNA.
Technical obstacles to generating influenza virus en-
tirely from cloned cDNA were overcome in 1999, when
our research group cloned cDNAs encoding all eight
segments of the A/WSN/33 (H1N1) virus between human
RNA polymerase I promoter and mouse RNA polymerase
I terminator sequences (Neumann et al., 1999) (Fig. 2).
virus possessing a single gene derived from cloned cDNA. In the
oprotein (NP) are mixed with in vitro synthesized vRNA to assemble
and infected with influenza helper virus (to provide the remaining seven
ontaining a cDNA that encodes one of the viral RNAs, flanked by RNA
cellular RNA polymerase I yields influenza vRNA that is replicated,
luenza helper virus. Both systems require stringent selection systems
s. Cells were transfected with eight plasmids that contain the RNA
polymerase I terminator. Cotransfection of cells with four plasmids for
n (PB1, PB2, PA, and NP) yields more than 1 3 108 infectious viruses
nine plasmids for the expression of all viral structural proteins permitsuenza
nucle
plexes
smid c
ion by
ith inf
cDNA
e RNA
scriptio
ls withhal mutations, thus allowing the generation of replication-incompetent
iral proteins.
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247MINIREVIEWAfter transfection of the resultant constructs in eukary-
otic 293T (human embryonic kidney) cells, transcription
by cellular RNA polymerase I yielded all eight vRNAs. In
the initial experiments, cells were also cotransfected
with plasmids expressing all nine structural proteins.
Despite the introduction of 17 plasmids into cells (8 for
the synthesis of RNA segments and 9 for protein expres-
sion), this approach yielded more than 1 3 107 infectious
viruses per milliliter of supernatant from cells transfected
with the plasmids. More recently, by improving the sys-
tem’s parameters, we have produced more than 1 3 108
infectious particles per milliliter of the supernatant, even
with use of only four proteins (PA, PB1, PB2, and NP) for
viral RNA transcription and replication. Although 12 plas-
mids are still required in our RNA polymerase I system
for influenza A virus generation, it remains one of the
most efficient systems yet reported (Pekosz et al., 1999).
We attribute this to the high transfection efficiency of
293T cells, leading to a pool of cells that receive the full
complement of constructs required to initiate virus rep-
lication. Further, RNA polymerase I is abundantly ex-
pressed in growing cells, thus ensuring efficient replica-
tion of RNA polymerase I constructs. In addition to its
high level of efficiency, the RNA polymerase I system is
quite simple, requiring only DNA cloning and transfec-
tion techniques, which are well established in most vi-
rology laboratories. Fodor et al. (1999) also reported the
generation of influenza A virus using a similar system; a
hepatitis delta virus ribozyme was used instead of the
RNA polymerase I terminator to produce vRNA possess-
ing the authentic 39 end sequence.
Most nonsegmented negative-sense RNA viruses
have been generated from antigenomic, positive-sense
cRNA (reviewed in Roberts and Rose, 1998). Either cRNA
or vRNA was used to produce hPIV3 (Durbin et al., 1997)
and Sendai virus (Kato et al., 1996); however, the latter
template was less efficient in viral generation. For influ-
enza virus production, negative-sense vRNA was supe-
rior to cRNA as a template for influenza virus production
(Hoffmann and Webster, 2000; our unpublished data),
possibly because with the nuclear RNA polymerase I
system, it is unlikely that negative-sense vRNAs hybrid-
ize with positive-sense mRNAs in the cytoplasm, which
is believed to affect the efficiency of virus generation in
the T7 RNA polymerase system. Furthermore, stretches
of uridine residues followed by hairpin structures, found
FIG. 3. The RNA polymerase I/II system for the generation of influen
a viral RNA flanked by RNA polymerase I promoter and terminator sequ
RNA polymerase II promoter and terminator sequences in a positive-
synthesis by cellular RNA polymerase I and in mRNA synthesis by ce
FIG. 4. Example of virus-like particles used to study the function of vir
structural proteins and with RNA polymerase I constructs for the synthe
contain only seven vRNAs, are used to infect fresh cells. Since proteins
their contribution to the viral life cycle can be studied. In this study, RNP rema
to RNP nuclear export (Neumann et al., 2000a).in the genomes of nonsegmented negative-sense RNA
viruses, may mimic the T7 RNA polymerase terminator
structure, causing premature termination of transcription.
By contrast, constraints that apply to the T7 RNA poly-
merase system, such as unwanted hybridization events
or premature termination, do not impinge on the effi-
ciency of virus generation in the RNA polymerase I sys-
tem.
A modification of the RNA polymerase I system, des-
ignated RNA polymerase I/II system, was reported by
Hoffmann et al. (2000) (Fig. 3). Briefly, a cDNA encoding
a viral segment was cloned in the negative-sense orien-
tation between RNA polymerase I promoter and termina-
tor sequences, and this cassette was in turn cloned in
the positive-sense orientation between an RNA polymer-
ase II promoter (CMV early promoter) and a polyadenyl-
ation sequence. Transcription by RNA polymerase I
yields negative-sense vRNA, whereas transcription by
RNA polymerase II results in positive-sense mRNA syn-
thesis. Thus, both vRNA and mRNA are generated from
the same template, circumventing the need for protein
expression constructs. Consequently, virus can be gen-
erated from 8 instead of 12 plasmids, reducing the num-
ber of plasmids required for virus generation. Therefore,
this system may be useful for cell lines that otherwise
cannot be transfected with a high level of efficiency. In
the RNA polymerase I/II system, both protein expression
and vRNA synthesis are achieved from the same tem-
plate. Therefore, this system does not allow generation
of virus-like particles lacking or containing lethal muta-
tions in one or more viral segments. These limitations
notwithstanding, both systems provide excellent tools for
experimental mutagenesis directed at understanding in-
fluenza virus biology.
The RNA polymerase I system described above allows
one to introduce any desired mutation into the genome of
influenza virus. This capability opens the way to address
such long-standing biologic issues as the nature of viral
regulatory sequences, structure–function relationships,
pathogenicity, and host cell tropism. Of particular impor-
tance is the identification of factors determining viral
pathogenicity.
Perhaps the most intriguing potential application of
reverse genetics systems for influenza virus generation
is the creation of live-attenuated virus vaccines. Current
inactivated vaccines effectively reduce the severity of
s. Cells are transfected with plasmids that contain a cDNA encoding
n a negative-sense orientation. This cassette is then inserted between
orientation. Transfection of these plasmids results in influenza vRNA
NA polymerase II.
ins. Cells are transfected with protein expression plasmids for all viral
even viral RNAs, omitting the NS vRNA. The resulting particles, which
d by the NS segment are not expressed in subsequently infected cells,za viru
ences i
sense
llular R
al prote
sis of s
encode
ined in the nucleus without the NS2 protein, indicating its contribution
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248 MINIREVIEWinfluenza-associated complications, but they do not pre-
vent infection. A cold-adapted live-attenuated vaccine
now in clinical trials (Maassab and Bryant, 1999) pro-
vides better protection than conventional inactivated vac-
cines in young children, but only comparable protection
in adults (Boyce and Poland, 2000). Moreover, it contains
only a limited number of amino acid replacements (Cox
et al., 1988; Herlocher et al., 1996), suggesting a potential
isk for emergence of a revertant virus upon use in a
arge population, even though the virus was phenotypi-
ally stable in clinical trials. Thus, there is room for
mprovement. The RNA polymerase I systems for virus
eneration are capable of producing a master strain of
nfluenza virus with multiple attenuating mutations in the
enes encoding internal proteins. In the near future,
everse genetics could be used to produce a high-yield
eassortant virus that possesses the HA and NA from a
urrently circulating strain. Moreover, reverse genetics
ystems could be exploited in the production of inacti-
ated vaccines, which currently are generated by con-
entional genetic reassortment procedures.
Influenza viruses may serve as potentially useful vec-
ors for gene transfer into mammalian cells. Indeed,
tudies with helper virus-dependent reverse genetics
ystems have demonstrated that influenza virus can ac-
ommodate additional genetic material. For several short
olypeptides, including the V3 loop of HIV-1 gp120 pro-
ein (Li et al., 1993a), a highly conserved epitope from the
ctodomain of HIV-1 gp41 (Muster et al., 1994, 1995), a
D81 T-cell epitope from the circumsporozoite protein of
Plasmodium yoelli (Li et al., 1993b), and a B-cell epitope
rom the outer membrane protein F of Pseudomonas
eruginosa (Gilleland et al., 1997), insertion in the anti-
enic sites of HA resulted in immune responses against
he foreign epitope. For the expression of foreign full-
ength proteins, the gene of interest can be physically
inked to one of the influenza virus genes. Protein ex-
ression can then be achieved by internal ribosomal
ntry sites (IRES) (Garcia-Sastre et al., 1994) or the foot-
nd-mouth disease virus 2A protease (Percy et al., 1994).
n these approaches, the foreign genetic material is
ranscribed or translated as part of an influenza viral
ene. Alternatively, foreign proteins can be expressed
rom an additional gene segment. Enami et al. (1991)
escued an artificial segment encoding wild-type NS1,
ut no NS2 protein, in a helper virus containing a ts
utation in NS1. Thus, this virus requires nine gene
egments for efficient replication at a nonpermissive
emperature, demonstrating the viability of influenza vi-
uses containing more than eight genomic segments. To
aintain additional segments in the absence of any
elective pressure, one could use mutant influenza virus
romoters that result in overreplication and/or overtran-
cription of the target gene (Neumann and Hobom,
995), an approach explored by Zhou et al. (1998) for the
i
leneration of recombinant influenza virus expressing the
2 glycoprotein of classical swine fever virus.
Safe and efficient delivery of foreign genetic material
nto cells could be achieved by virus-like particles
VLPs), i.e., particles that do not contain the full comple-
ent of viral RNAs. The expression of all viral (structural)
roteins and an influenza virus-like RNA encoding a
eporter gene results in the efficient generation of VLPs
Mena et al., 1996; Gomez-Puertas et al., 1999; Neumann
et al., 2000b). The delivery of foreign genes could then be
accomplished by transfection with protein expression
constructs encoding all viral structural proteins and with
RNA polymerase I constructs encoding the proteins re-
quired for replication and transcription (i.e., the polymer-
ase and NP, together with the gene of interest). The
resultant infectious particles could be used for a subse-
quent round of infection to deliver the foreign gene into
target cells, where the polymerase and NP proteins
would be expressed and drive replication and transcrip-
tion of the target gene, resulting in its expression. Since
the virus-like particles do not contain vRNAs encoding
structural proteins, no progeny particles are generated
after gene delivery, thus ensuring the safety of the deliv-
ery system. Furthermore, the availability of 15 HA and 9
NA subtypes would alleviate the risk of immunoresis-
tance to vector-generated proteins, allowing the re-
peated administration of VLPs.
Reports are now beginning to emerge that illustrate
the versatility of the new reverse genetics systems. Us-
ing the RNA polymerase I/II system, Hoffmann et al.
(2000) regenerated an A/Teal/HK/W312/97 (H6N1) virus
(isolated from a dead teal during the influenza virus
outbreak in Hong Kong in 1997). Furthermore, they gen-
erated reassortants between the A/WSN/33 (H1N1) and
the A/Teal/HK/W312/97 (H6N1) viruses and found that
the introduction of the A/WSN/33 HA or NA genes into
the Teal/HK/W312/97 background resulted in a signifi-
cant reduction in virus titers. Thus, the approach outlined
in this study may help researchers to elucidate the fac-
tors that determine viral pathogenicity (see Hatta et al., in
ress).
Two other studies used the RNA polymerase I system
o determine the function of influenza virus proteins.
eumann et al. (2000a) generated virus-like particles
hat entirely lacked or possessed mutations in the NS2
ene and examined the effect of these modifications on
RNP nuclear export (Fig. 4). This study confirmed, in the
ontext of viral infection, a previous finding by O’Neill et
l. (1998) that NS2 is critical for vRNP nuclear export,
ediated by a nuclear export signal in the N-terminal
egion of NS2. Insights into the role of the M2 ion-
hannel protein were provided by Watanabe et al. (2001).
iruses were generated that lacked or contained muta-
ions in the M2 transmembrane domain, indicating that
nfluenza A viruses can undergo multiple cycles of rep-
ication without M2 ion-channel activity in cell culture.
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249MINIREVIEWHowever, viruses defective in M2 ion-channel activity did
not efficiently replicate in mice, demonstrating that this
activity is critical for the viral life cycle. Similar ap-
proaches could be employed to determine the functions
of other influenza virus proteins or cellular events involv-
ing specific viral proteins.
RNA polymerase I-based systems for the generation of
influenza A virus provide, for the first time, powerful tools
for the modification of the influenza virus genome with
only minimal technical difficulties. With wider application
of this procedure, we can look forward to accelerated
progress in understanding the influenza virus life cycle,
the generation of live-attenuated vaccines, and the use
of influenza A virus as vaccine and gene delivery vectors.
Moreover, the RNA polymerase I system may prove use-
ful in the “de novo” synthesis of other viruses in the
Orthomyxoviridae family, including influenza B and C
iruses and Thogotovirus, as well as segmented nega-
ive-sense RNA viruses of the Bunyaviridae or Arenaviri-
ae families, which replicate in the cytoplasm of infected
ells. Flick and Pettersson (2001) demonstrated the nu-
lear export of RNA polymerase I transcripts during syn-
hesis of an Uukuniemi virus-like transcript (family Bun-
aviridae). Thus, the RNA polymerase I system may pro-
ide an alternative method for generating nonsegmented
egative-sense RNA viruses and could possibly result in
ore efficient production of these viruses than could be
chieved with the conventional T7 RNA polymerase sys-
em.
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